In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary ...

Co-CEO Bob Duggan highlighted significant progress with ivonescimab, Summit Therapeutics' lead investigational asset, emphasizing its potential impact on unmet medical needs. Key milestones included ...

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...

Crypto markets often pause before capital shifts direction. When Bitcoin slows near key levels, attention usually starts moving elsewhere. This rotation rarely happens all at once. It begins quietly, ...

Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion ...

Add Yahoo as a preferred source to see more of our stories on Google. PERTH AMBOY — The second phase of a massive three-phase project to rebuild NJ Transit's Raritan River Bridge began on a sweltering ...

GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...

The last time I wrote about Capricor Therapeutics (CAPR) it was with respect to a Seeking Alpha article entitled "Capricor: Maintaining Hold Rating In Light of Deramiocel Complete Response Letter".

The public comment period on Trump's sweeping changes to student-loan repayment has ended, bringing borrowers a step closer to finalization.